S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
The gold catalyst we’ve waited for (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
The gold catalyst we’ve waited for (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
The gold catalyst we’ve waited for (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ruling halts oil exports from Iraq's Kurdish area via Turkey
The gold catalyst we’ve waited for (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Finnish leadership condemns attack on veteran lawmaker
The gold catalyst we’ve waited for (Ad)
Challenger wins close race to lead United Auto Workers union
Canada pledges Great Lakes funding after Trudeau-Biden talks
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Technical issues at Lufthansa cause delays in Frankfurt

Illumina - ILMN Competitors

$220.00
+3.05 (+1.41%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$214.24
$220.44
50-Day Range
$194.01
$228.15
52-Week Range
$173.45
$371.16
Volume
754,647 shs
Average Volume
1.47 million shs
Market Capitalization
$34.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$249.40

ILMN vs. BIO, AVTR, BIO.B, GEHC, CNC, ALC, BNTX, SGEN, RMD, and ABC

Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Bio-Rad Laboratories (BIO), Avantor (AVTR), Bio-Rad Laboratories (BIO.B), GE HealthCare Technologies (GEHC), Centene (CNC), Alcon (ALC), BioNTech (BNTX), Seagen (SGEN), ResMed (RMD), and AmerisourceBergen (ABC). These companies are all part of the "medical" sector.

Illumina vs.

Illumina (NASDAQ:ILMN) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.

Illumina has a net margin of -96.12% compared to Bio-Rad Laboratories' net margin of -129.66%. Bio-Rad Laboratories' return on equity of 4.59% beat Illumina's return on equity.

Company Net Margins Return on Equity Return on Assets
Illumina -96.12% 3.79% 2.42%
Bio-Rad Laboratories -129.66% 4.59% 3.25%

88.0% of Illumina shares are owned by institutional investors. Comparatively, 64.4% of Bio-Rad Laboratories shares are owned by institutional investors. 0.1% of Illumina shares are owned by company insiders. Comparatively, 27.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Illumina has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Illumina presently has a consensus target price of $249.40, suggesting a potential upside of 13.36%. Bio-Rad Laboratories has a consensus target price of $664.75, suggesting a potential upside of 44.27%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Illumina.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina
2 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.38
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Bio-Rad Laboratories has lower revenue, but higher earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$4.58 billion7.58-$4.40 billion-$28.00-7.86
Bio-Rad Laboratories$2.80 billion4.87-$3.63 billion-$121.43-3.79

In the previous week, Illumina had 1 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 18 mentions for Illumina and 17 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.52 beat Illumina's score of 0.06 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Illumina
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
4 Negative mention(s)
4 Very Negative mention(s)
Neutral
Bio-Rad Laboratories
6 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Illumina received 710 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 66.69% of users gave Illumina an outperform vote while only 64.74% of users gave Bio-Rad Laboratories an outperform vote.

CompanyUnderperformOutperform
IlluminaOutperform Votes
1057
66.69%
Underperform Votes
528
33.31%
Bio-Rad LaboratoriesOutperform Votes
347
64.74%
Underperform Votes
189
35.26%

Summary

Illumina beats Bio-Rad Laboratories on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ILMN vs. The Competition

MetricIlluminaAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$34.28B$6.04B$4.35B$5.88B
Dividend YieldN/A0.39%2.32%4.53%
P/E Ratio-7.8620.0669.2011.31
Price / Sales7.5811.343,460.5556.13
Price / Cash46.7581.0827.62104.20
Price / Book5.2445.414.454.93
Net Income-$4.40B-$269.18M$114.96M$190.66M
7 Day Performance-2.03%-2.72%-0.85%0.68%
1 Month Performance11.91%-7.15%-6.62%-6.00%
1 Year Performance-35.62%-39.55%-16.08%-18.29%

Illumina Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO
Bio-Rad Laboratories
2.7417 of 5 stars
$466.21
-2.9%
$664.75
+42.6%
-18.3%$13.80B$2.80B-3.848,200News Coverage
AVTR
Avantor
2.4955 of 5 stars
$21.10
-2.3%
$29.33
+39.0%
-37.8%$14.23B$7.51B20.6914,500
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$464.10
flat
N/A-18.8%$13.74B$2.80B-3.827,900
GEHC
GE HealthCare Technologies
1.2036 of 5 stars
$74.77
-2.3%
$90.00
+20.4%
N/A$33.94B$18.34B0.0050,000News Coverage
CNC
Centene
3.3563 of 5 stars
$63.60
-2.6%
$96.94
+52.4%
-25.2%$35.06B$144.55B31.1874,300Analyst Report
ALC
Alcon
2.1697 of 5 stars
$66.67
-1.2%
$79.80
+19.7%
-11.5%$32.67B$8.72B99.5125,000News Coverage
BNTX
BioNTech
1.9699 of 5 stars
$133.68
+0.3%
$206.69
+54.6%
-20.4%$32.51B$22.45B3.023,082Upcoming Earnings
Analyst Report
Analyst Revision
SGEN
Seagen
2.149 of 5 stars
$198.37
-0.8%
$191.82
-3.3%
+42.9%$37.05B$1.96B-60.113,256Analyst Report
RMD
ResMed
2.6173 of 5 stars
$210.78
-1.4%
$263.17
+24.9%
-11.5%$31.42B$3.76B38.258,160
ABC
AmerisourceBergen
3.2015 of 5 stars
$153.44
-1.7%
$180.08
+17.4%
+1.1%$31.03B$238.59B18.6244,000News Coverage
This page (NASDAQ:ILMN) was last updated on 3/26/2023 by MarketBeat.com Staff